188 related articles for article (PubMed ID: 9890664)
1. A 65 kDa oncofetal protein (p65), proliferating cell nuclear antigen (PCNA) and Ki67 expression in breast cancer patients.
Niewiadomska H; Mirowski M; Stempien M; Olborski B; Blonski JZ; Hanausek M; Wierzbicki R
Neoplasma; 1998; 45(4):216-22. PubMed ID: 9890664
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.
Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ
Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis of expression of a 65 kDa oncofetal protein (p65), epidermal growth factor receptor (EGFR), oncogene c-erb B2 and tumor suppressor gene p53 protein products in breast cancer patients.
Niewiadomska H; Mirowski M; Stempień M; Błoński JZ; Czyz W; Switalska J; Matyga E; Hanausek M; Wierzbicki R
Neoplasma; 2000; 47(1):8-14. PubMed ID: 10870681
[TBL] [Abstract][Full Text] [Related]
4. The expression of products of oncogens c-erbB2 and EGFR and proliferating antigens Ki67 and PCNA in primary invasive ductal cancer of female breast.
Jeziorski A; Blonski JZ; Niewiadomska H
J Exp Clin Cancer Res; 2000 Mar; 19(1):61-7. PubMed ID: 10840938
[TBL] [Abstract][Full Text] [Related]
5. The expression of the proliferating antigen Ki67, PCNA and products of suppressor gene p53 in primary invasive ductal breast carcinoma.
Niewiadomska H; Jeziorski A; Olborski B
J Exp Clin Cancer Res; 1998 Dec; 17(4):503-10. PubMed ID: 10089075
[TBL] [Abstract][Full Text] [Related]
6. Proliferating cell nuclear antigen (PCNA) expression in patients with breast carcinoma in comparison to patients with benign breast diseases.
Kalogeraki A; Tzardi M; Datseris G; Kanavaros P; Karvelas C; Chalkiadakis G; Tsiftsis D; Delides G
In Vivo; 1994; 8(6):1053-6. PubMed ID: 7772736
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of polyclonal antibodies raised against P65 oncofetal protein in immunohistochemical diagnosis of ductal breast cancer.
Niewiadomska H; Mirowski M; Switalska J; Balcerczak E; Kubiak R; Wierzbicki R
J Exp Clin Cancer Res; 2004 Mar; 23(1):113-9. PubMed ID: 15149159
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
9. [Comparative studies on the biological significance of the marker for proliferation Ki-67-Antigen and PCNA in primary ovarian carcinoma].
Reitmaier M; Rudlowski C; Biesterfeld S; Rath W; Schröder W
Zentralbl Gynakol; 2000; 122(7):361-7. PubMed ID: 10951706
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of Ki-67, PCNA and S6K1/2 expression in human breast cancer.
Lyzogubov V; Khozhaenko Y; Usenko V; Antonjuk S; Ovcharenko G; Tikhonkova I; Filonenko V
Exp Oncol; 2005 Jun; 27(2):141-4. PubMed ID: 15995633
[TBL] [Abstract][Full Text] [Related]
11. Cell proliferative activity in intraductal papillary-mucinous neoplasms and invasive ductal adenocarcinomas of the pancreas: an immunohistochemical study.
Terada T; Ohta T; Kitamura Y; Ashida K; Matsunaga Y
Arch Pathol Lab Med; 1998 Jan; 122(1):42-6. PubMed ID: 9448015
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical assessment of proliferation rate of breast carcinoma cells using Ki-67, MIB-1 and anti-PCNA monoclonal antibodies.
Markiewski M; Domagała W
Pol J Pathol; 1996; 47(4):189-94. PubMed ID: 9097711
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt.
el-A Helal T; Khalifa A; Kamel AS
Anticancer Res; 2000; 20(3B):2145-50. PubMed ID: 10928168
[TBL] [Abstract][Full Text] [Related]
14. A cautionary note regarding the application of Ki-67 antibodies to paraffin-embedded breast cancers.
Gee JM; Douglas-Jones A; Hepburn P; Sharma AK; McClelland RA; Ellis IO; Nicholson RI
J Pathol; 1995 Nov; 177(3):285-93. PubMed ID: 8551391
[TBL] [Abstract][Full Text] [Related]
15. Localization of p53 and proliferating cell nuclear antigen in fine-needle aspirates of benign and primary malignant tumors of the human breast: an immunocytochemical study using supersensitive monoclonal antibodies and the biotin-streptavidin-amplified method.
Alexiev BA
Diagn Cytopathol; 1996 Nov; 15(4):277-81. PubMed ID: 8982580
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of proliferative cells.
Mokrý J; Nĕmecek S
Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove; 1995; 38(3):107-13. PubMed ID: 8685626
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
[TBL] [Abstract][Full Text] [Related]
18. PCNA/cyclin expression in breast carcinomas: its relationships with Ki-67, ER, PgR immunostainings and clinico-pathologic aspects.
Tuccari G; Rizzo A; Muscarà M; Giuffrè G; Barresi G
Pathologica; 1993; 85(1095):47-55. PubMed ID: 8100059
[TBL] [Abstract][Full Text] [Related]
19. Proliferating cell nuclear antigen immunostaining in breast cancer and its relation to prognosis.
Narita T; Funahashi H; Satoh Y; Takagi H
Jpn J Clin Oncol; 1993 Feb; 23(1):20-5. PubMed ID: 8096256
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of proliferating markers Ki-67, PCNA in gastric cancers.
Czyzewska J; Guzińska-Ustymowicz K; Lebelt A; Zalewski B; Kemona A
Rocz Akad Med Bialymst; 2004; 49 Suppl 1():64-6. PubMed ID: 15638377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
